P R O G R A M A N D A B S T R A C T S

First Page		Document Content
Date: 2014-03-16 21:58:34 Protease inhibitor Boehringer Ingelheim Technology Pharmaceutical industry in India ViiV Healthcare Merck & Co. NS5 Business Pharmaceutical industry Bristol-Myers Squibb Gilead Sciences		P R O G R A M A N D A B S T R A C T S Add to Reading List Source URL: www.iapac.org Download Document from Source Website File Size: 2,56 MB Share Document on Facebook

	Global Discovery to Development Innovation Forum - Speaker Bio Andreas Gollner - Research Group Leader Medicinal Chemistry - Boehringer Ingelheim PhD: University of Vienna (Organic Chemistry) Post Doc at Columbia Univer DocID: 1uA19 - View Document
	Microsoft Word - Boehringer Ingelheim 2010 ltr v2.doc DocID: 1ubPw - View Document
	January 3, 2017 Immediately Keri McGrath Happe; ; +Lauren Zierke; ; +Elanco Animal Health Completes Acquisition of Boehringer Ingelheim DocID: 1tQb1 - View Document
	Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. T DocID: 1skMX - View Document
	Reasons for CRADA Delays In the Past Ongoing • Sponsors hesitant and not DocID: 1rqkp - View Document